UNSPSC 51392903: Azanator maleate

This classification denotes a bronchodilator with the molecular formula C18H18N2O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63ISF1PDWX. The term azanator maleate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule azanator maleate under HS 29349990 and SITC 51579. As of Q4 2014, AZANATOR MALEATE remains US FDA's Preferred Term for this commodity. Azanator maleate bears US NLM identifiers UMLS ID C2698286 and NCI Concept Code C74219.

SMILES: CN1CCC(=C2C3CCCCC3OC4C2CCCN4)CC1.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51392903 Azanator maleate is a Commodity code that in recent state and local procurement activity covers pharmaceutical products used in emergency response and public health interventions, specifically naloxone and related drug-response systems. State and local health departments and county health agencies are the primary issuing bodies soliciting under this code, typically bundling pharmaceutical procurement with broader community health initiatives and opioid-response programming.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and quarterly delivery to the Seminole County Community Health Building in Sanford. The county required electronic bid submission through its e-Procurement Portal, inclusion of all shipping and delivery costs, drug-free workplace certification, and E-Verify compliance; the contract carried a two-year initial term with a one-year renewal option and was potentially funded through FEMA, introducing federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. The source shows limited recent activity under this specific code; the single opportunity identified is substantially older than the posting date and involves a product category (naloxone and drug deactivation systems) that diverges from the code's nominal pharmaceutical scope, suggesting the code sees minimal relevant state and local procurement volume.